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Chlamydia-specific cytotoxic T lymphocytes are able to control model infections but may be implicated in
disease pathogenesis. HLA-A2 peptide tetramers to Chlamydia trachomatis major outer membrane protein
258-266 (MOMP258-266) and MOMP260-268 were used to characterize HLA class I-restricted CD8 T cells
in Gambian children aged 4 to 15 years with clinical signs of active trachoma and/or infection with C.
trachomatis. The frequencies of circulating HLA-A2 tetramer binding cells (TBC) were determined in whole
blood samples by flow cytometric analysis. Initial screening of subjects with an anti-HLA-A2 antibody con-
firmed the presence of either HLA-A2 or HLA-A28. These were subsequently further divided by molecular
subtyping. The C. trachomatis-specific HLA-A2 peptide tetramers were able to bind T cells with receptors from
subjects which were restricted by either the HLA-A2 or the HLA-A28 restriction element. In this population,
the median value of C. trachomatis-specific CD8 T cells was 0.02%, with frequencies of up to 3.71% of CD8
T cells reactive with a single tetramer in a minority of subjects. TBC were detected more often in subjects who
were infected at the ocular surface, and their presence was associated with infection episodes of longer
duration. Detection of C. trachomatis-specific TBC was not associated with the presence of disease or with the
estimated load of ocular C. trachomatis infection at the time of sample collection. High frequencies of C.
trachomatis-specific cells did not predict subsequent appearance or resolution of the clinical disease signs of
active trachoma.
Chlamydia trachomatis is the intracellular bacterium respon-
sible for the conjunctival disease trachoma. Trachoma has two
distinct phases with various degrees of severity. Active tra-
choma, in which C. trachomatis is most frequently isolated,
usually occurs in young children. Under the World Health
Organization grading scheme, this is classified as trachomatous
inflammation, follicular (TF), which may appear with or with-
out intense inflammation—trachomatous inflammation, in-
tense (TI) (34). Active disease episodes are more common and
last longer in children than in adults from the same community
living where the disease is endemic, suggesting that acquired
resistance or immunity may develop with age (3). Scarring
trachoma, in which C. trachomatis can rarely be isolated, oc-
curs most frequently in adults. Development of scar tissue is
thought to be related to the adaptive immune response respon-
sible both for the clearance of C. trachomatis and in some cases
the induction of tissue pathology (22).
HLA class I-restricted CD8 effector cells (cytotoxic T lym-
phocytes [CTL]), usually with CD4 T-cell help, maintain im-
munity to viral infections (16, 28, 32, 36). Because C. tracho-
matis is an obligate intracellular pathogen, mechanisms similar
to those that control viral replication and infection may be
effective in chlamydial infection. For many years, it was con-
sidered that chlamydial antigens were not expressed on the
surface of infected human cells, since after its entry into host
cells C. trachomatis is enclosed by a membrane-bound vacuole
that resists lysosome fusion. Evidence gathered from several
groups since the mid 1990s indicates that CTL can be gener-
ated in response to infection with C. trachomatis, suggesting
that antigens are made available for presentation, though the
importance of these CTL in natural disease and infection re-
mains unclear (4, 13, 21, 30). In tissue sections from human
conjunctiva (27) and in primate animal models, CD8 cells
clearly accumulate at the site of infection (35). Furthermore, in
this primate model, Van Voorhis et al. (35) demonstrated
elevated levels of perforin mRNA in cells isolated from the site
of infection. In human studies, Burton et al. (5) have also
shown that subjects with ocular infection or clinical signs of
disease had elevated levels of perforin mRNA in cells collected
from the conjunctiva.
Work in vitro and in murine models has demonstrated that
Chlamydia-specific CTL have the ability to lyse infected targets
and to produce cytokines (gamma interferon [IFN-]) in re-
sponse to antigenic stimulation (13, 21, 30). CTL have been
used to identify antigens, such as major histocompatibility com-
plex (MHC) class I-accessible protein 1, which were not detected
by other techniques (11). In humans, C. trachomatis-specific CTL
have been identified in subjects exposed to chlamydial infection
(12, 13, 17, 19, 20). In these and other studies, CTL generated to
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a number of C. trachomatis epitopes that were restricted by com-
mon and disease-associated HLA types were used to identify
peptide-specific responses (12, 15, 24). Human CTL epitopes
have also been mapped in several major C. trachomatis and
C. pneumoniae proteins and their HLA restriction described;
for example, multiple overlapping epitope-dense regions have
been mapped in C. trachomatis major outer membrane protein
(MOMP) (18).
The in vitro techniques required to generate and test for
CTL are often labor intensive and require significant numbers
of cells. HLA-peptide tetramers or pentamers offer an alter-
native technique to measure the frequency of cells bearing
epitope-specific T-cell receptors (TCR) that have the ability to
bind to antigen. This direct analysis can describe the frequency
of naturally circulating cells without any in vitro restimulation
or manipulation.
Kim et al. have described several HLA-peptide tetramers spe-
cific for C. trachomatis MOMP which were able to bind to CD8
T cells from blood and in vitro cultures of peripheral blood mono-
nuclear cells (PBMC) of patients with documented chlamydial
sexually transmitted infection (19). Additionally, Chlamydia-spe-
cific HLA-B27 tetramers for a number of antigens have been used
to identify specific CD8 T cells from the synovial fluid mono-
nuclear cells of subjects with a C. trachomatis-induced reactive
arthritis, albeit at low frequency (2, 20). For C. pneumoniae,
HLA-A0201-restricted tetramers specific for T-cell epitopes in
heat shock proteins 60 and 70 have described the presence of
low-frequency populations in cultured PBMC of some subjects
with coronary heart disease (7). One common feature appears to be
that without in vitro restimulation, Chlamydia-specific tetramer-
binding cell (TBC) frequencies are very low.
In order to study a large number of subjects, we selected two
tetramers covering overlapping epitopes of MOMP that fall in
an epitope-dense region and are restricted by a common HLA
type, HLA-A0201, to screen subjects from a region where
trachoma is endemic.
The prevalence of HLA-A2 in the Gambian population is
25%; however, a further consideration is the fact that a number
of HLA-A types can present identical peptide epitopes. For this
reason, HLA-A2 is considered a supertype, consisting of HLA-
A0201, -A0202, -A0203, -A0206, and -A6802. HLA-
A6802 is itself part of a serological determinant, HLA-A28.
HLA-A28 has three molecular subtypes, HLA-A6801, -A6802,
and -A6901. The prevalence of HLA-A28 in the Gambian pop-
ulation is 20%. HLA-A6802 constitutes 95% of the HLA-
A28 in Gambian populations (9). Computational models of pre-
dictive epitope binding have been validated by binding and
presentation of HLA-A2 nonamer peptides by HLA-A6802 (10,
23, 29). The same techniques can be used to look at cross-reac-
tivity of TCR-pMHC complexes. Thus, if the reactive surfaces of
HLA-A2 and -A6802 are sufficiently similar, any TCR reactive
to one should be reactive to the other, such that TCR restricted
by HLA-A6802 may bind HLA-A2–pMHC. The lack of struc-
tural data for TCR, however, is a major constraint in the predic-
tion of the reactivity of TCR-pMHC complexes. We show that
HLA-A2–peptide tetramers can cross-react with CD8 TCR
from HLA-A6802 subjects but not with CD8 TCR from HLA-
A2- or -A6802-negative subjects. We then analyzed whether
either the presence or the frequency of TBC is associated
with clinical signs of active trachoma, infection, or the con-
junctival C. trachomatis load in HLA-A2 subjects.
MATERIALS AND METHODS
Subjects. A subgroup of 159 subjects from a larger-cohort study consented to
venipuncture (1 to 5 ml). The entire cohort consisted of 346 children, aged 4 to
15 years, from nine villages in The Gambia. Ocular examinations and samples
were collected every 2 weeks over a period of 28 weeks. At each visit, a clinical
examination of the conjunctiva was made and a digital photograph of the everted
eyelid was taken. Trachoma was graded according to the World Health Organi-
zation simplified grading scheme by an experienced trachoma examiner. Swabs
were used to collect cellular material from the conjunctiva of the right eye, a dry
swab for DNA and a swab for RNA collected in RNAlater buffer [Ambion
(Europe) Ltd., Cambridge, United Kingdom]. Children with TI were offered
treatment immediately with 20-mg/kg oral azithromycin. Children with TF and
their household members were offered treatment according to the national
program policy at the end of the study period. The joint Gambian Government-
Medical Research Council Ethics Committee and the Ethics Committee of the
London School of Hygiene & Tropical Medicine approved the design and pro-
cedures of this study.
C. trachomatis ocular load. The conjunctival C. trachomatis load was deter-
mined as described elsewhere (5). Briefly, conjunctival swabs from the right eye
were immediately collected into the RNA stabilization buffer RNAlater [Ambion
(Europe) Ltd., Cambridge, United Kingdom]. RNA was then extracted accord-
ing to the manufacturer’s instructions with the RNeasy 96 Qvac system (QIAGEN
Ltd., Crawley, United Kingdom). Additional precautions were taken to remove
copurified DNA by treatment with RNase-free DNase I and further incubations and
washes with the buffers RW1 and RPE (QIAGEN). Before the final elution, the
96-well Qvac plates were dried by centrifugation for 15 min at 200  g and then
incubation at 70°C for 15 min. RNA was then eluted with 2  65 l of RNase-free
H2O for 5 min at room temperature. Samples were stored at70°C until assayed by
quantitative real-time reverse transcription-PCR with QuantiTech SYBR Green
reverse transcription-PCR kits (QIAGEN Ltd., Crawley, United Kingdom). The
extent of productive chlamydial infection was determined with primers specific forC.
trachomatis 16S rRNA (25).
HLA-A2/28 staining. Fluorescein isothiocyanate-labeled anti-HLA-A2/28 (VH
Bio Ltd., Newcastle, United Kingdom) was used to rapidly identify subjects from
the study population with the appropriate HLA type. Briefly, 5 l of fluorescein
isothiocyanate-conjugated anti-HLA-A2/28 was added to 50 l of whole blood
and the mixture was incubated at 4°C for 15 min. Red blood cells were then lysed
by addition of 1.5 ml of 1 fluorescence-activated cell sorter (FACS) lysing
solution by vortex mixing and 10 min of incubation at room temperature. Cells
were harvested by centrifugation and resuspended in 100 l of FACS wash
before immediate acquisition of fluorescence in the mononuclear cell gate
(50,000 events). Results were expressed as histogram plots of event counts
versus fluorescence intensity. Cells from previously confirmed HLA-A2/28-
positive and -negative individuals served as controls.
HLA-A2 and -A28 (HLA-A6801, -A6802, and -A6901)-specific typing by
PCR. HLA class I typing was carried out by PCR with the sequence-specific
primers shown in Table 1. All samples were checked for inhibition of PCR and
DNA integrity by amplification of the 2-microglobulin gene. Template DNA
was prepared by extraction and purification of DNA from conjunctival swabs as
described elsewhere (6). Two to 10 ng of genomic DNA in 2 l of H2O was
added to 23 l of a standard hot-start PCR mixture (QIAGEN Ltd., Crawley,
United Kingdom) containing primers and cycled under the conditions described
in Table 1, footnote a.
Tetramer staining and FACS analysis. Previously identified CTL epitopes
from the MOMP CS4 epitope cluster were selected; HLA-A2 MOMP258 (258R
LNMFTPYI266)- and HLA-A2 MOMP260 (260NMFTPYIGV268)-restricted tet-
ramers were synthesized by Proimmune (Oxford, United Kingdom). Both of
these peptide sequences contain the preferred residues for HLA-A0201; these
are L or M at P2 and I or V at P9. One microliter of phycoerythrin-conjugated
tetramer was added to 150 l of heparinized whole blood, and the mixture was
incubated at 37°C for 15 min. Fluorochrome-conjugated anti-CD8 monoclonal
antibody PerCP (BD Sciences, Oxford, United Kingdom) was then added, and
the mixture was incubated for a further 15 min at room temperature. Red blood
cells were lysed by the addition of 3 ml of 1 FACS lysing solution (BD Sciences,
Oxford, United Kingdom). Samples were vortexed and allowed to stand for 15
min at room temperature in the dark. Cells were then collected by centrifugation
at 800  g for 5 min. The supernatant was discarded and the pellet resuspended
with 3 ml of FACS wash solution. Cells were then collected by centrifugation as
before. The pellet was finally resuspended in 200 l of FACS fix (phosphate-
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buffered saline containing 2% formaldehyde). Fluorescence data were acquired
immediately or within 12 h on a FACScalibur flow cytometer (BD Sciences,
Oxford, United Kingdom). For each analysis, 250,000 events gated on lympho-
cyte size and granularity were acquired. The percentages of tetramer cells in the
CD8 positive gate were then expressed. All FACS data were analyzed with
FCSExpress v2.0 software. HLA-A2-negative subjects were tested in the same
manner to control for nonspecific tetramer binding. Each tetramer staining
experiment included this negative control, which was later used to define the
range of non-tetramer-specific binding. This percentage was not subtracted from
the values obtained in HLA-A2 or -A28 subjects. The data are presented as
unadjusted percentages. Laboratory staff were blind to clinical disease status and
infection status.
Statistical applications. The data from the longitudinal study were managed
by Microsoft Access. For statistical analysis, data were extracted, manipulated,
and analyzed in Stata v8.0. The tetramer frequencies were highly skewed, even
after log transformation; therefore, results were tested for significance with
nonparametric Kruskal-Wallis and Mann-Whitney tests. In the subgroup of sub-
jects selected for tetramer studies, the potential number of data collection points
was 1,288. We made 1,132/1,288 clinical observations and 1,084/1,288 PCR tests
for ocular C. trachomatis. For the construction of disease duration data, concor-
dant observations of disease/infection status at 2-weekly follow-up were taken to
imply that the state was unchanged between the observations. Where a single
observation is missing between concordant observations, continuity was assumed
and where a missing observation intervened between changes of state, the state
was assumed to have changed midway between the observations.
RESULTS
Study population demographics, clinical disease, prevalence
of infection, and frequency of HLA-A2/28. There were 114
females (33%) and 232 males (67%) in the cohort; the median
age of study participants was 8 years (range, 4 to 15 years).
Seventy-four children (21%) had clinical signs of trachoma (TF
and/or TI) at their first examination, and 18 children (5.2%)
had evidence of trachomatous scarring. Eighty-two subjects
had incident active trachoma at follow-up. The frequency of
HLA-A2/28 by serology in those subjects from whom blood
samples were obtained was 75/159 (47.1%) by FACS analysis.
Molecular subtyping of HLA-A2 and -A28 (HLA-A6801,
-A6802, and -A6901) identified 45/159 (28.3%) and 39/159
(24.5%), respectively. Eight samples that were HLA-A2/28
positive by FACS could not be confirmed by PCR. Sixteen
samples that were negative by FACS were either HLA-A2
positive (n 	 10) or HLA-A28 positive (n 	 6) by PCR.
Eighty-six subjects were included in the tetramer analysis.
None of these subjects had TI at the time the blood sample was
collected. Of these, 42 were HLA-A2 positive, 24 were HLA-
A28 positive, and 20 were HLA-A2/28 negative controls. In the
subgroup analyzed for tetramer staining with a PCR-confirmed
HLA type (n	 86), there were 35 females and 51 males, with a
median age of 9 (range, 4 to 15) years at the time of venipunc-
ture. Seventeen children had signs of active trachoma, and
three had evidence of trachomatous scarring. Infection (C.
trachomatis 16S rRNA) was present in 27.9% (24/86) of the
subjects in which tetramer staining was undertaken.
A minority of subjects from communities where trachoma is
endemic have circulating C. trachomatisMOMP-specific CD8
cells. Sixty-six HLA-A2/28-positive subjects and 20 HLA-A2/28-
negative samples were tested for reactivity with the HLA-A2
Chlamydia-specific tetramers. HLA-A2/28-negative subjects were
used to establish the range of nonspecific background obtained by
FIG. 1. The number of TBC detected is associated with the pres-
ence of HLA-A2 or -A28. The number of subjects with a percentage of
TBC above the maximum obtained with HLA-A2/28 (shown in paren-
theses) was as follows for HLA-A2 subjects: MOMP258 level of0.04,
n	 6 (range, 0.05 to 1.71%); MOMP260 level of0.08, n	 11 (range,
0.09 to 3.8%). For HLA-A28 subjects, it was as follows: MOMP258
level of0.04, n	 1 (0.06%); MOMP260 level of0.08, n	 7 (range,
0.09 to 1.35%). Cumulative total TRC, i.e., percent MOMP258 plus
MOMP260 of 0.1: HLA-A2 subjects, n 	 11 (range, 0.11 to 5.51);
HLA-A28 subjects, n 	 8 (range, 0.13 to 1.36) (data not shown).
TABLE 1. Primer sequences, binding positions, product sizes, and thermal cycling conditions used in HLA PCR typinga
Primer Sequence Target (relative exonbinding position)
PCR parameters
Product
size (bp)Annealing
temp (°C)
No. of
cycles
HLA#A2F GTGGATAGAGCAGGAGGGT HLA-A exon 2 (149–167) 70 7 491
HLA#A2R CCAAGAGCGCAGGTCCTCT HLA-A exon 3 (110–127) 65 30
55 3
AL#6 CGGAATGTGAAGGCCCAG HLA-A exon 2 (192–209) 66 5 447
AL#H CAAGAGCGCAGGTCCTCT HLA-A exon 3 (110–127) 56 30
50 5
2M#5 AGATTCAGGTTTACTCACG 2-M exon 2 (132–150) 66 5 264
2M#6 TAACTATCTTGGGCTGTGA 2-M exon 3 (377–395) 50 35
a All PCRs included 15 min of heat activation of DNA polymerase enzyme at 95°C. Each denaturation and extension phase was 15 s at 94°C and 30 s at 72°C. The
annealing temperatures and the cycle numbers are indicated. All exon locations and product sizes are based on sequences with the following accession numbers:
HLA-A*0201, AJ575565; HLA-A*68, AJ633570; 2-M, M17987.
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FIG. 2. FACS plots from four different HLA-A2-positive subjects (a to i). Panels j and k are plots from a single HLA-A2/A28-negative subject.
The subject number is shown above each plot. Panel a shows the R1 gate for lymphocytes used in all subsequent plots. Panels b and c show the
percent positive for either MOMP258 or MOMP260 for the subject shown in panel a. The gate and the percent CD8 tetramer are indicated
in each plot. Panels b and c show results for a subject positive for both MOMP258 and MOMP260. Panels d and e show results for a subject positive
for MOMP258 but not MOMP260. Panels f and g show MOMP260-reactive but not MOMP258-reactive cells. Panels h and i show no cells with
reactivity with either MOMP258 or MOMP260.
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flow cytometry with these tetramers. Figure 1 shows the distri-
bution of tetramer reactivity and the percentage of TBC to
each individual tetramer, irrespective of clinical status or in-
fection, in HLA-A2 and HLA-A28 subjects compared to non-
HLA-A2/28 subjects. This clearly indicates that tetramer-spe-
cific cells are present in the PBMC of HLA-A2 subjects in a
population resident where trachoma is endemic. The range of
tetramer reactivity in non-HLA-A2/28 subjects was 0 to 0.04%
(MOMP258) and 0 to 0.08% (MOMP260). Only responses
above these values were considered indicative of tetramer-
reactive cells in HLA-A2 subjects. For further analysis, the
values obtained with both tetramers were summed (MOMP258
plus MOMP260) to yield a total TBC percentage. As a cutoff,
the highest combined level obtained in a single individual was
used (0.1%).
Of 42 HLA-A2 subjects, 10 subjects had total TBC frequen-
cies above 0.1%. The remaining 32 subjects had levels of
0.1% and so were considered negative. Of 24 HLA-A28
subjects, 8 were positive by these criteria. Since HLA-A28
subjects may represent a subset of subjects whose T cells may
cross-react with tetramers containing HLA-A2, these subjects
were eliminated from subsequent analysis but were not con-
sidered suitable as HLA-A2 negative controls. Figure 2 shows
the typical staining obtained by flow cytometry in whole blood
from four separate HLA-A2 individuals and a single non-
HLA-A2/28 subject. This demonstrates the complete range of
binding patterns. Typical FACS plots of TBC to each tetramer
are shown in Fig. 2a to k, with frequencies of TBC for indi-
vidual tetramers as follows: MOMP258, 0.002 to 0.212%;
MOMP260, 0 to 1.39%.
TBC are detected more often and at higher frequencies in
the presence of C. trachomatis infection. Tetramer frequencies
and their relationship with clinical signs of active trachoma and
the presence of C. trachomatis infection at the time the blood
sample was taken were examined. Detection of TBC in
HLA-A2 subjects was associated with the presence of infec-
tion, and higher TBC frequencies (percent) were found in the
presence of clinical signs (Fig. 3). However, TBC frequency
and the load of ocular infection (16S rRNA quantity) could not
be objectively summarized with a simple summary statistic.
Correlation is the most appropriate analysis tool; however, a
significant number of observations are below the sensitivity of
each test (
10 copies of C. trachomatis 16S rRNA and 
0.1%
TBC). This leads to clustering of the data, which generates bias
in a simple correlation. Given the small sample size, this is not
open to more complex modeling to account for clustering.
Data are therefore presented in a simple scatterplot (Fig. 4).
Detection of TBC and the frequency of total TBC were asso-
ciated with infection but not associated with clinical disease
signs. Thus, clinical signs without coincident infection (C. tra-
chomatis 16S rRNA) or clinical disease signs with infection
FIG. 3. TBC are associated with the presence of infection. Median
values (ranges) are as follows: uninfected subjects, 0.03% (0.02 to
1.31%); infected subjects, 0.15% (0.02 to 5.51%) (Mann-Whitney P 	
0.02). Of 42 HLA-A2-positive subjects, 10 had ocular infection. Of
these, eight had TBC values of 0.1%. Of the 32 subjects without
infection, only 2 subjects had TBC values of 0.1%.
FIG. 4. Percent TBC (total TBC) and extent of C. trachomatis
shedding or load of infection at the conjunctiva. For presentation on a
log scale, zero values were treated by the addition of a constant (C.
trachomatis 16S rRNA load 1) to each value in the data set examined
(42 HLA-A2-positive subjects with or without infection).
FIG. 5. Percent TBC is not associated with clinical observation of
disease (P 	 0.52) but is associated with infection (P 	 0.05). The
numbers of subjects in whom the percent TBC was 0.1 were as
follows: normal, 4/26; clinical disease signs only, 0/6; clinical disease
signs and infection, 4/6; infection only, 2/4. The numbers of subjects in
the affected groups were limited, and thus the statistical inference is
underpowered.
VOL. 74, 2006 C. TRACHOMATIS MOMP-SPECIFIC CD8 T LYMPHOCYTES 1569
were also independent of TBC frequency (Fig. 5). In this anal-
ysis, only infection at the time of blood sampling is considered.
The control group was infection free at the time of sampling.
Because these communities live where trachoma is endemic,
all individuals within this age range will experience infection
and are likely to be antigen experienced. This is shown by equal
levels of whole-blood IFN- recall responses to chlamydial
elementary bodies (data not shown) between infected and un-
infected subjects.
TBC are more often detected during longer infection epi-
sodes. From the longitudinal data, it is possible to search for
associations between TBC frequency and the number of dis-
ease episodes, duration of disease episodes, number of infec-
tion episodes, and duration of infection and to examine these
together (Table 2). Clinical disease sign durations were esti-
mated in the same manner for each subject in which tetramers
were tested. Subjects in whom TBC were detected had longer
infection episodes: the median duration (range) of current
infection in TBC-positive subjects was 33.5 (0 to 146) days,
compared to 14 (0 to 96) days in the TBC-negative group (P 	
0.0048). A larger number of infection episodes was also asso-
ciated with detection of TBC (P	 0.013). The range of disease
sign episodes was zero to six, but the frequency of TBC was not
associated with the number of disease episodes during follow-
up. The duration of disease episodes was also independent of
TBC frequency.
DISCUSSION
We have demonstrated that TBC are present in the periph-
eral blood of patients exposed to ocular C. trachomatis and that
the presence of TBC is dependent on the presence of HLA-
A2/28. This was important in the absence of a T-cell line
reactive to these epitopes which could be used to confirm
tetramer specificity when each staining reaction was con-
ducted. The prevalence of HLA-A2/28 in this population was
48% by FACS analysis, which is similar to that found in pre-
vious studies (1, 9). We used molecular typing to confirm the
presence of HLA-A2 and -A28 after tetramer staining. Thus,
by eliminating cross-reactive HLA-A28 subjects from the anal-
ysis and studying a number of non-HLA-A2/28 subjects with
and without infection or clinical disease signs, it was possible to
establish a range of reactivity and define a stringent positive
binding result.
In two separate studies, Kim et al. (17, 19) described C.
trachomatis MOMP-specific T cells with CTL activity and ad-
dressed the question of whether such cells are representative
of in vivo responses to infection. Cells reactive to several
MOMP epitopes were characterized with HLA-A2–peptide
tetramers in patients with documented genital C. trachomatis
infection. Frequencies in a range of 0.01 to 0.2% were identi-
fied, and it was possible to culture and isolate TBC with CTL
activity. Two MOMP epitopes were predominantly studied,
MOMP258-266 and MOMP260-268, but it was noted that the
frequencies obtained were significantly lower than those ob-
served with some viral infections. With these same epitopes in
HLA-A2–peptide tetramers, we obtained frequencies in a
range 0.01 to 3.7% (for 42 HLA-A2 subjects, mean and median
values of 0.18% and 0.02%, respectively, were obtained for a
single tetramer [MOMP260-268]) in peripheral blood of sub-
jects in communities where trachoma is endemic. This indi-
cated that subjects in communities where trachoma is endemic
recognized these epitopes; however, it is still not established if
these are immunodominant epitopes. In other human studies
in which Chlamydia-specific tetramers have been used, even
cells at the site of inflammatory disease (isolated from the
synovial fluid of reactive-arthritis patients) were present at very
low frequencies (0.02 to 0.09%). In both cases, only after
isolation and expansion in vitro were appreciable levels of TBC
obtained (2, 19).
Nevertheless, our data indicate that in subjects exposed to
the ocular serovars, TBC to these conserved MOMP epitopes
are generated. Among the possible explanations for the low
frequency of TBC in patients with genital or synovial chlamyd-
ial infection are the low number of subjects tested and the
inability to characterize these subjects in terms of the amount
of C. trachomatis exposure, antigen load, and temporal obser-
vations of disease and infection. A longitudinal cohort study in
communities where trachoma is endemic has allowed us the
opportunity to observe disease and infection in a temporal
manner and measure microbiological correlates such as anti-
gen load. In this case, we can address the questions posed by
Kim et al. (19) about the use of HLA-peptide tetramers to
identify, quantify, and study immunopathogenic consequences
of infection.
Associations of frequency of TBC with disease and infection
parameters were tested both in a cross-sectional study and
longitudinally. At the time of sample collection, the frequency
of TBC was dependent on evidence of ocular C. trachomatis
infection but independent of clinical disease signs. A number
of subjects had subclinical infection, i.e., were C. trachomatis
16S rRNA positive without clinical signs of trachoma. Similar
findings have been found in other studies in which TBC and
viral replication have been examined. In these cases, it has been
suggested that TBC have little role in the inhibition of local
infection but are effective in protection against dissemination (8).
Evidence which may support this comes from the observation that
strong C. trachomatis CTL responses are induced in animal mod-
els by C. trachomatis serovar L when introduced by a route which
leads to disseminated infection (30).
Examination of disease and infection over the study period
TABLE 2. Longitudinal data showing the relationship(s) of disease
signs and infection in HLA-A2 subjects with detectable TBC
compared to those without detectable TBC
Parameter and TBC level n Median Range P value
Duration of infection (days)
0.1 10 33.5 0–146 0.0048
0.1 32 14 0–91
Duration of disease signs (days)
0.1 10 13 0–190 0.72
0.1 32 0 0–203
No. of infection episodes
0.1 10 2 0–3 0.013
0.1 32 1 0–5
No. of disease episodes
0.1 10 2 0–6 0.96
0.1 32 1.5 0–5
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revealed an interesting pattern of responses linked to infection.
Longer durations of infection were associated with the detec-
tion of peripheral blood TBC, suggesting either that TBC
result from long-duration infections or that they could be re-
sponsible for increasing the duration of infection.
Since the duration and number of disease episodes were
independent of TBC frequency, this may indicate that TBC are
not directly immunopathogenic. Kim et al. (19) offered the
explanation that low levels of TBC in genital C. trachomatis
infection were due to the fact that the sexually transmitted
infection subjects studied were not persistently infected or
re-exposed or reinfected. We demonstrate that, in subjects
exposed to ocular C. trachomatis infection, the levels of TBC
for these MOMP epitopes in trachoma are dependent on cur-
rent infection but not disease signs.
Longer duration of ocular C. trachomatis infection is asso-
ciated with a higher frequency of TBC, perhaps suggesting that
the rapid expansions and contractions of this cell population
are in response to infection; however, it is likely that a number
of infection episodes are required before TBC can be detected.
A further possibility is that the TBC quantitative peripheral
response is not an important parameter. Recent evidence that
CD4 CD25 T regulatory cells can prevent CTL homing to
sites of infection implies that these cells control the effective-
ness of the response (33). Thus, differing levels of peripheral
TBC observed in disease and infection may not be represen-
tative of TBC that are able to migrate to the site of infection in
the conjunctival epithelium. It is also a possibility that a bal-
ance between T regulatory cells and T effector cells (CTL,TH1,
or TH2) may lead to chronic infection, such that over time
the number of TBC expands and they become more easily
detectable.
There is no direct demonstration that MOMP can serve as a
substrate for the chlamydial type III secretory apparatus and
thus gain access to the cytosol, where it may enter antigen
presentation pathways. Several studies have shown that chla-
mydial substrates of type III secretion can be translocated into
the cytosol of infected host cells (14) and that these can be-
come targets for CTL. In addition, CD8 T cells specific for
MOMP have been repeatedly demonstrated and these can
produce IFN- and/or lysis of infected target cells. These
CD8 T cells most likely occur as a result of antigen cross-
presentation (31). This is consistent with the finding that the
levels of TBC reflect current infection status. Once TBC are
stimulated by cross-presentation, in order to be effective they
must be able to recognize C. trachomatis-infected cells at the
conjunctival surface. Infected conjunctival epithelial cells are
not known to cross-present antigen, and therefore the MOMP-
specific T cells may not recognize these as target cells. With no
mechanism to respond to these cells, expand at these sites, or
effect clearance of the pathogen, they will not be maintained
once the organism load declines. Infected epithelial cells can
serve as target cells in vitro. Beatty and Stephens (4) have
shown that infected L cells transfected with ICAM-1 can serve
as targets for class I-restricted cells. However, in vitro-infected
human fibroblasts could not be lysed by Chlamydia-specific
CD8 T cells restricted by polymorphic MHC class Ia antigens,
irrespective of ICAM-1 status. Only T cells restricted by less
polymorphic MHC class Ib molecules could lyse cells. Inter-
estingly, infected fibroblasts were able to stimulate either
CD8 T-cell population to secrete IFN- (13). Complemen-
tary and contradictory results were presented by Matyszak and
Gaston (26), who also demonstrated the development of two
types of CD8 CTL restricted by either classical MHC class I
or nonclassical MHC class I. These clones, however, were
equally able to lyse infected target cells (U937). Few studies
have used infected epithelial cells as CTL targets; however,
Kim et al. (19) successfully used C. trachomatis serovar E-in-
fected, HLA-A2-transfected ME180 human cervical epithelial
cells as a target cell population for peptide-restimulated and
tetramer-enriched effector cells. It follows, then, that host cell
targets must play an important and major role in the effective-
ness of the response.
In diseases in which persistent or repeated infection appears
important in morbidity, these data show the importance of
longitudinal follow-up, since we find that TBC are associated
with duration of infection but not signs of disease. The fre-
quencies of MOMP-specific, class I-restricted T cells detected
in peripheral blood are not the determinants of immune re-
sponse-mediated resolution. It is possible that the observed
HLA-A6802 association with severe conjunctival scarring in
Gambian populations living where trachoma is endemic (9) is
due to a class I-restricted T cell, e.g., a TBC which curtails the
effective immune response. Since it is the accepted view that
the number or intensity of infection episodes drives scarring,
our data could support the view that subclinical or inapparent
infection is also important in this process.
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